Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

  • Merrimack Pharmaceuticals (NASDAQ:MACK) shares increased by 195.8% to $11.83 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 28.1 million, which is 113716.7% of its average full-day volume over the last 100 days. The company's market cap stands at $158.6 million. As per the press release, Q3 earnings came out 4 days ago.
  • NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock moved upwards by 42.4% to $1.78. As of 12:30 EST, NeuroBo Pharmaceuticals's stock is trading at a volume of 33.4 million, which is 3695.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 million.
  • OptimizeRx (NASDAQ:OPRX) stock moved upwards by 28.85% to $18.71. The current volume of 319.8K shares is 124.1% of OptimizeRx's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $337.2 million. The company's, Q3 earnings came out yesterday.
  • Kala Pharmaceuticals (NASDAQ:KALA) stock increased by 27.76% to $6.67. Kala Pharmaceuticals's stock is trading at a volume of 7.1 million shares as of 12:30 EST. This is 23646.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.7 million. As per the news, the Q3 earnings report came out yesterday.
  • Histogen (NASDAQ:HSTO) stock moved upwards by 24.57% to $1.24. As of 12:30 EST, Histogen's stock is trading at a volume of 6.1 million, which is 1297.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.0 million.
  • Health Catalyst (NASDAQ:HCAT) stock rose 23.8% to $8.01. As of 12:30 EST, Health Catalyst's stock is trading at a volume of 1.8 million, which is 173.5% of its average full-day volume over the last 100 days. The company's market cap stands at $438.3 million. As per the press release, Q3 earnings came out yesterday.

Losers

  • Clovis Oncology (NASDAQ:CLVS) stock fell 74.2% to $0.25 during Wednesday's regular session. Clovis Oncology's stock is trading at a volume of 33.3 million shares as of 12:30 EST. This is 1118.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $36.5 million. As per the news, the Q3 earnings report came out today.
  • Athersys (NASDAQ:ATHX) shares fell 54.89% to $0.58. The current volume of 6.3 million shares is 447.0% of Athersys's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $7.0 million.
  • Trevena (NASDAQ:TRVN) shares fell 31.32% to $0.12. As of 12:30 EST, Trevena's stock is trading at a volume of 2.5 million, which is 371.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.0 million. As per the press release, Q3 earnings came out today.
  • Emergent BioSolutions (NYSE:EBS) stock decreased by 29.35% to $13.94. Trading volume for Emergent BioSolutions's stock is 2.0 million as of 12:30 EST. This is 331.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $695.0 million. The company's, Q3 earnings came out yesterday.
  • Baudax Bio (NASDAQ:BXRX) stock declined by 23.75% to $0.14. Baudax Bio's stock is trading at a volume of 1.3 million shares as of 12:30 EST. This is 71.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.7 million. As per the press release, Q3 earnings came out yesterday.
  • Revelation Biosciences (NASDAQ:REVBU) shares fell 20.93% to $0.27. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.